Go to main content

  1. Home
  2. Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support

UK - Department of Health and Social Care (DHSC)

Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support

Disclaimer: The data for this page has been produced from IATI data published by UK - Department of Health and Social Care (DHSC). Please contact them (Show Email Address) if you have any questions about their data.

Programme Data Last Updated: 20/12/2022



A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme


The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus: 1. Improve clinical management of neonatal sepsis This work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme. 2. Developing new and improved treatments for multi drug-resistant infections in neonates This work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates. 3. Accelerating regulatory approval and access in high burden LMICs Through this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed.

Status - Implementation More information about Programme status
Programme Spend More information about Programme funding
Participating Organisation(s) More information about implementing organisation(s)

This site uses cookies

We use Google Analytics to measure how you use the website so we can improve it based on user needs. Google Analytics sets cookies that store anonymised information about how you got to the site, the internal pages you visit, how long you spend on each page and what you click on while you're visiting the site. Read more